|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR17 |
Gene summary for WDR17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR17 | Gene ID | 116966 |
| Gene name | WD repeat domain 17 | |
| Gene Alias | WDR17 | |
| Cytomap | 4q34.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8IZU2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116966 | WDR17 | HCC1 | Human | Liver | HCC | 5.09e-09 | 8.86e-01 | 0.5336 |
| 116966 | WDR17 | HCC2 | Human | Liver | HCC | 1.41e-14 | 1.01e+00 | 0.5341 |
| 116966 | WDR17 | HCC5 | Human | Liver | HCC | 3.01e-14 | 8.14e-01 | 0.4932 |
| 116966 | WDR17 | HTA12-23-1 | Human | Pancreas | PDAC | 1.27e-03 | 6.03e-01 | 0.3405 |
| 116966 | WDR17 | HTA12-25-1 | Human | Pancreas | PDAC | 3.33e-03 | 4.07e-01 | 0.313 |
| 116966 | WDR17 | HTA12-26-1 | Human | Pancreas | PDAC | 2.63e-13 | 7.33e-01 | 0.3728 |
| 116966 | WDR17 | HTA12-29-1 | Human | Pancreas | PDAC | 9.44e-28 | 6.40e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR17 | SNV | Missense_Mutation | rs140987021 | c.1213N>A | p.Asp405Asn | p.D405N | Q8IZU2 | protein_coding | tolerated(0.83) | benign(0.023) | TCGA-DD-AADU-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| WDR17 | SNV | Missense_Mutation | c.403N>C | p.Cys135Arg | p.C135R | Q8IZU2 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-ED-A7XO-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| WDR17 | SNV | Missense_Mutation | rs748882959 | c.1639C>T | p.Arg547Cys | p.R547C | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G3-A5SL-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WDR17 | SNV | Missense_Mutation | c.2207N>T | p.Asn736Ile | p.N736I | Q8IZU2 | protein_coding | deleterious(0.01) | possibly_damaging(0.472) | TCGA-G3-A7M7-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| WDR17 | SNV | Missense_Mutation | novel | c.1672N>A | p.Pro558Thr | p.P558T | Q8IZU2 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| WDR17 | SNV | Missense_Mutation | c.3338N>A | p.Pro1113His | p.P1113H | Q8IZU2 | protein_coding | deleterious(0.04) | possibly_damaging(0.717) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| WDR17 | SNV | Missense_Mutation | novel | c.910C>A | p.Pro304Thr | p.P304T | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WDR17 | SNV | Missense_Mutation | rs766138696 | c.3523N>G | p.Arg1175Gly | p.R1175G | Q8IZU2 | protein_coding | deleterious(0) | benign(0.146) | TCGA-05-5425-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | gefitinib | PD |
| WDR17 | SNV | Missense_Mutation | c.149N>T | p.Gly50Val | p.G50V | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.941) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| WDR17 | SNV | Missense_Mutation | c.1462N>A | p.Trp488Arg | p.W488R | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-50-6593-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |